Computational Molecular Biology 2015, Vol. 5, No. 5, 1-9
9
Conflict of interest
All authors are accepted for publishing this article. No
authors will conflict this article.
References
Baekelandt M, Kristensen GB, Nesland JM, TropéCG, Holm R. 1999. “Clinical
significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in
advanced ovarian cancer.” J Clin Oncol, 17: 2061
Cancer Fact sheet N°297". Feb 2014. “World Health Organization”. Retrieved 10
June 2014.
Dumitrescu RG, Cotarla I.2005. “Understanding breast cancer risk--where
do we stand in 2005?” J Cell Mol Med, 9:208–21
Elvidge G. 2006. “Microarray expression technology: from start to finish.”
Pharmacogenomics 7: 123–134.
Fearon ER and Vogelst ein B. 1990. “ A genetic model for colorectal
tumorigenesis.” Cell, 61, 759–767.
Golub TR. 2001. “Genome-wide viewsofcancer.” N EnglJ Med344:601–602
Honrado E, Osorio A, PalaciosJ, Benitez J. 2006. “Pathology andgene expression
of hereditary breast tumors associated with BRCA1, BRCA2 and
CHEK2 gene mutations.” Oncogene, 25:5837–45
Kupryjańczyk J, Szymańska T, Madry R, Timorek A, Stelmachów J, Karpińska G,
Rembiszewska A, Ziółkowska I, Kraszewska E, Debniak J, Emerich J,
Ułańska M, Płuzańska A, Jedryka M, Goluda M, Chudecka-Głaz A,
Rzepka-Górska I, Klimek M, Urbański K, Breborowicz J, Zieliński J,
Markowska J. 2003. “Evaluation of clinical significance of TP53,
BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated
with platinum-based regimen.” Br J Cancer, 88: 848–854
Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de
Jong PE, Coresh J, Gansevoort RT. Chronic Kidney Disease Prognosis
Consortium. 2010. “Association of estimated glomerular filtration rate
and albuminuria with all-cause and cardiovascular mortality in general
population cohorts: a collaborative meta-analysis. ” Lancet,
375:2073–2081.
Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal
YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills
GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. 2012.
“Resistance to BRAF inhibition in BRAF-mutant colon cancer can be
overcome with PI3K inhibition or demethylating agents.” Clin Cancer
Res, 19(3):657-67.
Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jakobsen A. 2004.
“Prognostic significance of p53, Her-2, and EGFR overexpression in
borderline and epithelial ovarian cancer.” Int J Gynecol Cancer 14:
1086–1096
Prashantha Nagaraja, Kavya Parashivamurthy, Nandini Sidnal, Siddappa
Mali, Dakshyani Nagaraja, and Sivarami Reddy. 2013, “ Analysis of
gene expression on ngn3 gene signaling pathway in endocrine
pancreatic cancer.” Bioinformation, 9(14): 739–747.
Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D. 2009. “Supervised
Risk Predictor of Breast Cancer Based on Intrinsic Subtypes.” Journal
of Clinical Oncology 27: 1160–1167.
R Core Team, 2012. “ R: a language and environment for statistical
computing. Vienna, Austria: R Foundation for Statistical Computing.”
.
Robinson MD, McCarthy DJ, Smyth GK. 2010. “ EdgeR: a bioconductor
package for differential expression analysis of digital gene expression
data.” Bioinformatics, 26:139–140.
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M,
Nakamura Y, White R, Smits AM and Bos JL. 1988. “ Genetic
alterations during colorectal-tumor development. ” N. Engl. J.
Med., 319, 525–532.
Wang X1, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA,
Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno
NT. 2013. “TIG1 promotes the development and progression of
inflammatory breast cancer through activation of Axl kinase.” Cancer
Res, 73(21):6516-25.
Yu X, Vazquez A, Levine AJ, Carpizo DR. 2012. “Allele-specific p53
mutant reactivation.” Cancer Cell, 21(5):614-25.
